Subtopic Deep Dive
Desmoid Tumors/Aggressive Fibromatosis
Research Guide
What is Desmoid Tumors/Aggressive Fibromatosis?
Desmoid tumors, also known as aggressive fibromatosis, are rare, locally invasive fibroblastic proliferations driven by CTNNB1 mutations and beta-catenin activation, occurring sporadically or associated with FAP.
Investigations emphasize CTNNB1 mutations like S45F correlating with local recurrence in sporadic cases (Lazar et al., 2008, 443 citations). Management has shifted from aggressive surgery to watchful waiting and systemic therapies including imatinib and pazopanib. Over 20 papers from the provided list detail molecular prognosticators and phase II trial outcomes.
Why It Matters
CTNNB1 S45F mutation predicts postoperative recurrence, guiding risk-stratified management (Colombo et al., 2013, 179 citations). Imatinib showed 25% partial response in aggressive fibromatosis phase II trial (Chugh et al., 2010, 234 citations). European consensus recommends conservative approaches, reducing morbidity from surgery (Kasper et al., 2017, 388 citations). Pazopanib achieved disease control in progressive desmoids (Toulmonde et al., 2019, 189 citations). γ-Secretase inhibitor PF-03084014 induced tumor regression in adults (Kummar et al., 2017, 187 citations).
Key Research Challenges
Predicting Local Recurrence
CTNNB1 mutations like S45F associate with higher recurrence post-surgery (Lazar et al., 2008, 443 citations; Colombo et al., 2013, 179 citations). Distinguishing sporadic from FAP-associated cases remains critical for prognosis. Lack of standardized molecular testing limits personalized risk assessment.
Optimizing Non-Surgical Therapy
Imatinib yields partial responses but variable efficacy across patients (Chugh et al., 2010, 234 citations). Pazopanib and methotrexate-vinblastine show promise in progressive disease, yet optimal sequencing unclear (Toulmonde et al., 2019, 189 citations). Resistance mechanisms to targeted agents require elucidation.
Standardizing Management Guidelines
Shift to watchful waiting reduces morbidity but needs validation beyond consensus (Kasper et al., 2017, 388 citations; Dangoor et al., 2016, 475 citations). FAP-associated desmoids demand tailored surveillance. Prospective trials scarce for rare tumor biology.
Essential Papers
UK guidelines for the management of soft tissue sarcomas
Adam Dangoor, Beatrice Seddon, Craig Gerrand et al. · 2016 · Clinical Sarcoma Research · 475 citations
Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
Alexander J. Lazar, Daniel Tuvin, Shohrae Hajibashi et al. · 2008 · American Journal Of Pathology · 443 citations
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
B. Kasper, Christina Baumgarten, J. Santiago García et al. · 2017 · Annals of Oncology · 388 citations
Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease
Bernd Kasper, Philipp Ströbel, Peter Hohenberger · 2011 · The Oncologist · 315 citations
Abstract Desmoid tumors describe a rare monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Although histologically benign, desmoids are loca...
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification
Françoise Galateau-Sallé, Andrew Churg, Victor L. Roggli et al. · 2016 · Journal of Thoracic Oncology · 277 citations
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Rashmi Chugh, J. Kyle Wathen, Shreyaskumar Patel et al. · 2010 · Clinical Cancer Research · 234 citations
Abstract Purpose: Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of connective tissues that can be locally aggressive despite wide surgical resection and/or ...
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
Veridiana Pires de Camargo, Mary Louise Keohan, David R. D’Adamo et al. · 2010 · Cancer · 212 citations
Abstract BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examina...
Reading Guide
Foundational Papers
Start with Lazar et al. (2008, 443 citations) for CTNNB1 mutation-recurrence correlation; Kasper et al. (2011, 315 citations) for clinical features; Chugh et al. (2010, 234 citations) for imatinib trial benchmarks.
Recent Advances
Kasper et al. (2017, 388 citations) European consensus; Toulmonde et al. (2019, 189 citations) pazopanib phase 2; Kummar et al. (2017, 187 citations) γ-secretase inhibitor activity.
Core Methods
CTNNB1 sequencing for S45F detection; phase II trials with RECIST response; consensus guideline development via EuroNet/EORTC.
How PapersFlow Helps You Research Desmoid Tumors/Aggressive Fibromatosis
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve CTNNB1 mutation papers, then citationGraph on Lazar et al. (2008) reveals 443-citation network linking Colombo et al. (2013) and European consensus (Kasper et al., 2017). findSimilarPapers expands to imatinib trials like Chugh et al. (2010).
Analyze & Verify
Analysis Agent applies readPaperContent to extract S45F mutation recurrence odds ratios from Lazar et al. (2008), verifies claims with CoVe against Chugh et al. (2010) imatinib response rates, and runs PythonAnalysis to meta-analyze progression-free survival across 5 trials using pandas for GRADE evidence grading.
Synthesize & Write
Synthesis Agent detects gaps in post-2017 pazopanib sequencing via contradiction flagging between Toulmonde et al. (2019) and Kasper et al. (2017), generates LaTeX reports with latexEditText for management algorithms, latexSyncCitations for 10-paper bibliographies, and exportMermaid for CTNNB1 pathway diagrams.
Use Cases
"Run meta-analysis of CTNNB1 S45F mutation recurrence rates from provided papers"
Research Agent → searchPapers('CTNNB1 S45F desmoid') → Analysis Agent → readPaperContent(Lazar 2008, Colombo 2013) → runPythonAnalysis(pandas meta-analysis with GRADE scoring) → CSV export of pooled OR=2.5 (95% CI 1.8-3.4).
"Draft LaTeX review on desmoid management shift citing Kasper 2017 and Chugh 2010"
Synthesis Agent → gap detection(Kasper 2017 consensus vs surgery data) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF with beta-catenin figure) → peer review simulation.
"Find code for desmoid tumor growth modeling from related papers"
Research Agent → paperExtractUrls(systemic therapy papers) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow delivers Python simulator for fibromatosis progression calibrated to Chugh et al. (2010) data.
Automated Workflows
Deep Research workflow conducts systematic review of 20+ desmoid papers, chaining searchPapers → citationGraph → GRADE grading for management evidence synthesis. DeepScan applies 7-step analysis to verify imatinib efficacy claims from Chugh et al. (2010) with CoVe checkpoints. Theorizer generates hypotheses on γ-secretase inhibitor resistance from Kummar et al. (2017) pathway data.
Frequently Asked Questions
What defines desmoid tumors?
Desmoid tumors are locally invasive fibroblastic proliferations with CTNNB1 mutations causing beta-catenin stabilization, occurring sporadically or FAP-associated (Lazar et al., 2008).
What are key methods for studying desmoids?
Molecular analysis detects CTNNB1 S45F mutations via sequencing; phase II trials evaluate imatinib and pazopanib response rates (Chugh et al., 2010; Toulmonde et al., 2019).
What are seminal papers?
Lazar et al. (2008, 443 citations) links CTNNB1 mutations to recurrence; Kasper et al. (2017, 388 citations) provides European consensus on conservative management.
What open problems exist?
Optimal therapy sequencing post-pazopanib failure; prospective validation of watchful waiting; resistance to γ-secretase inhibitors (Kummar et al., 2017).
Research Soft tissue tumor case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Desmoid Tumors/Aggressive Fibromatosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Soft tissue tumor case studies Research Guide